WESTLAKE VILLAGE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (NASDAQ:TTRX) ("Turn" or the "Company"), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, today announced it has entered into a global supply, development, and license agreement with Medline, the largest provider of medical-surgical products and supply chain solutions serving all points of care. The agreement establishes a long-term collaboration to develop, manufacture, and commercialize products leveraging Turn's proprietary PermaFusion® delivery platform. Turn Therapeutics CEO Bradley Burnam commented, "Partnering with Medline represents a tr

WESTLAKE VILLAGE, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (NASDAQ:TTRX) ("Turn" or the "Company"), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, provides a shareholder update outlining continued progress in the advancement of its clinical programs while highlighting the flexibility of its financing strategy following its dilution-sparing direct listing. Capital Strategy and AlignmentTurn chose a direct listing structure to prioritize flexibility and long-term shareholder alignment. By bypassing traditional crossover rounds and IPO share issuance, early shareholders maintained their ownership position

LOS ANGELES, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (NASDAQ:TTRX) today announced the launch of a broad communications initiative, featuring a recurring webinar series for shareholders and a forthcoming Founder Blog authored by patient-turned-founder and CEO, Bradley Burnam. "It is an uncommon step to maintain constant engagement with shareholders, partners, and the broader healthcare community," said Bradley Burnam, Founder and CEO of Turn Therapeutics. "But this company was built by a deeply engaged community, and we intend to continue that conversation as we grow." The Founder Blog will publicly share ongoing company updates, research insights, and perspectives on Turn's

WESTLAKE VILLAGE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics ("Turn" or the "Company"), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, announces the appointment of Kent E. Kester, MD, FACP, FIDSA, FASTMH to its Board of Directors. Dr. Kester is a globally recognized infectious disease physician and R&D leader with extensive experience spanning clinical development, translational medicine, vaccine and anti-infective innovation, and public-private collaboration. A retired U.S. Army Colonel, he has held senior leadership roles across industry and academia, including as Commander of the Walter Reed Army Inst

WESTLAKE VILLAGE, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics ("Turn" or the "Company"), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, announces the appointment of Arthur Golden, a senior corporate board advisor with extensive experience in M&A transactions, shareholder relations, compliance, and governance, to its Board of Directors. He has decades of experience as a corporate director, most recently as a Director of Emerson Electric where he served for 24 years and chaired the Corporate Governance and Finance Committees and was a member of the Executive Committee. Mr. Golden brings decades of experienc

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

WESTLAKE VILLAGE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics ("Turn" or the "Company"), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, announces the appointment of Kent E. Kester, MD, FACP, FIDSA, FASTMH to its Board of Directors. Dr. Kester is a globally recognized infectious disease physician and R&D leader with extensive experience spanning clinical development, translational medicine, vaccine and anti-infective innovation, and public-private collaboration. A retired U.S. Army Colonel, he has held senior leadership roles across industry and academia, including as Commander of the Walter Reed Army Inst

WESTLAKE VILLAGE, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics ("Turn" or the "Company"), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, announces the appointment of Arthur Golden, a senior corporate board advisor with extensive experience in M&A transactions, shareholder relations, compliance, and governance, to its Board of Directors. He has decades of experience as a corporate director, most recently as a Director of Emerson Electric where he served for 24 years and chaired the Corporate Governance and Finance Committees and was a member of the Executive Committee. Mr. Golden brings decades of experienc

8-K - Turn Therapeutics Inc. (0002023016) (Filer)

424B5 - Turn Therapeutics Inc. (0002023016) (Filer)

8-K - Turn Therapeutics Inc. (0002023016) (Filer)

8-K - Turn Therapeutics Inc. (0002023016) (Filer)